For the quarter ending 2026-03-31, RARE has $1,296,000K in assets. $1,525,000K in debts. $175,000K in cash and cash equivalents.
| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Cash and cash equivalents | 175,000 | 421,000 | 202,510 | 176,306 |
| Marketable securities | 238,000 | 259,000 | 222,738 | 311,279 |
| Accounts receivable, net | 121,000 | 158,000 | 112,543 | 124,464 |
| Inventory | 55,000 | 52,000 | 52,200 | 46,498 |
| Prepaid expenses and other assets | 68,000 | 61,000 | 53,215 | 61,241 |
| Total current assets | 657,000 | 951,000 | 643,206 | 719,788 |
| Property, plant and equipment, gross | - | 380,000 | - | - |
| Less accumulated depreciation | - | 136,000 | - | - |
| Property, plant, and equipment, net | 239,000 | 244,000 | 249,961 | 255,763 |
| Marketable securities | 121,000 | 57,000 | 22,067 | 51,454 |
| Intangible assets, net | 174,000 | 176,000 | 172,943 | 174,733 |
| Goodwill | 44,000 | 44,000 | 44,406 | 44,406 |
| Other assets | 61,000 | 60,000 | 57,862 | 60,121 |
| Total assets | 1,296,000 | 1,532,000 | 1,190,445 | 1,306,265 |
| Lease liabilities | - | 12,000 | 12,142 | 11,766 |
| Accounts payable | 42,000 | 31,000 | 40,573 | 34,242 |
| Accrued liabilities | 194,000 | 265,000 | 220,526 | 180,792 |
| Liabilities for sales of future royalties | 72,000 | 69,000 | 65,545 | 63,863 |
| Other liabilities | 17,000 | 7,000 | 1,236 | 2,581 |
| Total current liabilities | 325,000 | 384,000 | 340,022 | 293,244 |
| Lease liabilities | - | 24,000 | 21,691 | 24,531 |
| Deferred tax liabilities | 30,000 | 30,000 | 30,058 | 30,058 |
| Liabilities for sales of future royalties | 1,128,000 | 1,147,000 | 763,735 | 782,748 |
| Other liabilities | 42,000 | 20,000 | 18,780 | 17,398 |
| Total liabilities | 1,525,000 | 1,605,000 | 1,174,286 | 1,147,979 |
| Noncontrolling interest | 7,000 | 7,000 | 7,000 | 7,000 |
| Common stock, par value of 0.001 per share - 250,000,000 shares authorizedoutstanding - 96,442,027 in 2025 and 92,484,330 in 2024 | - | - | 96 | 96 |
| Treasury stock, at cost, 0.3 in 2026 and 0.2 in 2025 | 10,000 | 8,000 | 7,991 | 7,991 |
| Deferred compensation obligation | 10,000 | 8,000 | 7,991 | 7,991 |
| Additional paid-in capital | 4,481,000 | 4,451,000 | 4,411,531 | 4,374,333 |
| Accumulated other comprehensive loss | 0 | 1,000 | 820 | -268 |
| Accumulated deficit | -4,717,000 | -4,532,000 | -4,403,288 | -4,222,875 |
| Total stockholders' equity (deficit) | -236,000 | -80,000 | 9,159 | 151,286 |
| Total liabilities, noncontrolling interest and stockholders' equity (deficit) | 1,296,000 | 1,532,000 | 1,190,445 | 1,306,265 |
Ultragenyx Pharmaceutical Inc. (RARE)
Ultragenyx Pharmaceutical Inc. (RARE)